20/20 Biolabs, Inc. AIDX
develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases.
offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, and (ii)
OneTest for Longevity, which measures inflammatory biomarkers, that was launched in February 2026 (the Longevity test is also being branded
"OneTest for Workplace Wellness" when marketed to self-insured employers). Both tests are run in our CAP (College of American
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $2.0M | $1.8M | — |
| Cost of revenue | $1.4M | $1.4M | — |
| Gross profit | $604.5K | $360.3K | — |
| R&D | $592.6K | $1.3M | — |
| SG&A | $3.3M | $4.8M | — |
| Total operating expenses | $3.9M | $6.0M | — |
| Operating income | -$3.3M | -$5.7M | — |
| Interest expense | $156.2K | $12.6K | — |
| Net income | -$3.7M | -$5.6M | — |
| EPS, basic | -0.76 | -1.16 | — |
| EPS, diluted | -0.76 | -1.16 | — |
| Shares, diluted (wtd. avg.) | 4.9M | 4.8M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $1.0M | $1.8M | $4.1M |
| Receivables | $200.0K | $135.3K | $68.8K |
| Inventory | $116.2K | $47.2K | — |
| Total current assets | $1.5M | $2.0M | — |
| Property, plant and equipment | $56.7K | $116.7K | — |
| Other intangibles | $202.3K | $205.5K | — |
| Total assets | $4.1M | $3.6M | — |
| Accounts payable | $868.5K | $372.3K | — |
| Total current liabilities | $2.5M | $1.4M | — |
| Total liabilities | $4.2M | $2.1M | — |
| Retained earnings | -$33.2M | -$29.5M | — |
| Total equity | -$19.2K | $1.5M | $4.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$1.9M | -$2.6M | — |
| Depreciation and amortisation | $63.3K | $116.0K | — |
| Stock-based compensation | $516.2K | $2.2M | — |
| Financing cash flow | $1.2M | $293.3K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-040545.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | $1.8M | $2.0M |
| Gross profit | — | $360.3K | $604.5K |
| Net income | — | -$5.6M | -$3.7M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Regulation FD disclosure Item 7.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Results announced Item 2.02
- Material agreement signed Item 1.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8734
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ULS | UL Solutions Inc. | $14.83B | 45.9x | 6.4% |
| NEO | NEOGENOMICS INC | $2.13B | — | 10.1% |